Dr. Martens plc (LON:DOCS – Get Free Report) insider Ije Nwokori bought 232 shares of the stock in a transaction dated Friday, September 11th. The stock was purchased at an average cost of GBX 65 per share, for a total transaction of £150.80.
Ije Nwokori also recently made the following trade(s):
- On Tuesday, August 11th, Ije Nwokori bought 179 shares of Dr. Martens stock. The shares were purchased at an average price of GBX 84 per share, with a total value of £150.36.
- On Thursday, June 25th, Ije Nwokori purchased 118,516 shares of Dr. Martens stock. The shares were purchased at an average cost of GBX 72 per share, with a total value of £85,331.52.
Dr. Martens Price Performance
LON:DOCS opened at GBX 67.50 on Friday. The company has a quick ratio of 1.13, a current ratio of 2.61 and a debt-to-equity ratio of 108.85. The firm has a market cap of £646.08 million, a PE ratio of 28.12, a price-to-earnings-growth ratio of 6.40 and a beta of 0.26. Dr. Martens plc has a 12 month low of GBX 59.15 and a 12 month high of GBX 100.87. The company’s 50-day moving average price is GBX 76.57 and its two-hundred day moving average price is GBX 70.45.
Wall Street Analyst Weigh In
Check Out Our Latest Analysis on DOCS
About Dr. Martens
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage.
Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.
See Also
- Five stocks we like better than Dr. Martens
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.
